TAB1 sirna

TAB1 siRNA (Human)

Cat. Num. AAA8219263

• Gene Names: TAB1; 3'-Tab1; MAP3K7IP1
• Reactivity: Human
• Applications: RNA Interference (RNAi)
• Purity: > 97%
• Synonyms: TAB1; TAB1 siRNA (Human); MAP3K7IP1; TGF-beta-activated kinase 1 and MAP3K7-binding protein 1; Mitogen-activated protein kinase kinase kinase 7-interacting protein 1; TGF-beta-activated kinase 1-binding protein 1; TAK1-binding protein 1; TAB1 sirna

• Host: Synthetic
• Reactivity: Human
• Specificity: TAB1 siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
• Purity/Purification: > 97%
• Form/Format: Lyophilized powder
• Sequence Length: 504

• Applicable Applications for TAB1 sirna: RNA Interference (RNAi)
• Quality Control: Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
• Directions for Use: We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
• Components: We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human TAB1 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
• Preparation and Storage: Shipped at 4 degree C. Store at -20 degree C for one year.

Related Product Information for TAB1 sirna

siRNA to inhibit TAB1 expression using RNA interference

NCBI and Uniprot Product Information

• NCBI GI #: 5174703
• NCBI GeneID: 10454
• NCBI Accession #: NP_006107.1
• NCBI GenBank Nucleotide #: NM_006116.2
• UniProt Accession #: Q15750; Q2PP09; Q8IZW2
• Molecular Weight: 49,917 Da
• NCBI Official Full Name: TGF-beta-activated kinase 1 and MAP3K7-binding protein 1 isoform alpha
• NCBI Official Synonym Full Names: TGF-beta activated kinase 1/MAP3K7 binding protein 1
• NCBI Official Symbol: TAB1
• NCBI Official Synonym Symbols: 3'-Tab1; MAP3K7IP1
• NCBI Protein Information: TGF-beta-activated kinase 1 and MAP3K7-binding protein 1
• UniProt Protein Name: TGF-beta-activated kinase 1 and MAP3K7-binding protein 1
• Protein Family: TGF-beta-activated kinase 1 and MAP3K7-binding protein
• UniProt Gene Name: TAB1
• UniProt Synonym Gene Names: MAP3K7IP1; TAK1-binding protein 1
• UniProt Entry Name: TAB1_HUMAN

NCBI Description

The protein encoded by this gene was identified as a regulator of the MAP kinase kinase kinase MAP3K7/TAK1, which is known to mediate various intracellular signaling pathways, such as those induced by TGF beta, interleukin 1, and WNT-1. This protein interacts and thus activates TAK1 kinase. It has been shown that the C-terminal portion of this protein is sufficient for binding and activation of TAK1, while a portion of the N-terminus acts as a dominant-negative inhibitor of TGF beta, suggesting that this protein may function as a mediator between TGF beta receptors and TAK1. This protein can also interact with and activate the mitogen-activated protein kinase 14 (MAPK14/p38alpha), and thus represents an alternative activation pathway, in addition to the MAPKK pathways, which contributes to the biological responses of MAPK14 to various stimuli. Alternatively spliced transcript variants encoding distinct isoforms have been reported. [provided by RefSeq, Jul 2008]

Uniprot Description

TAB1: May be an important signaling intermediate between TGFB receptors and MAP3K7/TAK1. May play an important role in mammalian embryogenesis. Interacts with XIAP and BIRC7. Interacts with TRAF6 and MAP3K7; during IL-1 signaling. Identified in the TRIKA2 complex composed of MAP3K7, TAB1 and TAB2. Ubiquitous. 2 isoforms of the human protein are produced by alternative splicing.

Protein type: Activator; Motility/polarity/chemotaxis

Chromosomal Location of Human Ortholog: 22q13.1

Cellular Component: nucleoplasm; protein complex; cytoplasm; endosome membrane; cytosol

Molecular Function: protein binding; mitogen-activated protein kinase p38 binding; enzyme activator activity; kinase activator activity; protein complex binding; catalytic activity

Biological Process: heart morphogenesis; I-kappaB kinase/NF-kappaB cascade; activation of MAPK activity; in utero embryonic development; MyD88-independent toll-like receptor signaling pathway; stress-activated MAPK cascade; toll-like receptor 3 signaling pathway; activation of NF-kappaB transcription factor; toll-like receptor 2 signaling pathway; toll-like receptor 10 signaling pathway; MyD88-dependent toll-like receptor signaling pathway; toll-like receptor 5 signaling pathway; transforming growth factor beta receptor signaling pathway; activation of MAPKKK activity; toll-like receptor signaling pathway; JNK cascade; innate immune response; toll-like receptor 9 signaling pathway; toll-like receptor 4 signaling pathway; lung development